Consequently, all of them were withdrawn after regulatory approval, with the exception of blinatumomab, a bispecific antibody targeting CD19 that uses two mouse-derived single chain variable fragment and lacks Fc segment and that is currently used for the treatment of acute lymphoblastic leukemia (ALL) in adults and children [41,42]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.